Literature DB >> 28395086

Regional Overlap of Pathologies in Lewy Body Disorders.

Martí Colom-Cadena1,2, Oriol Grau-Rivera3, Lluís Planellas4, Catalina Cerquera4,5, Estrella Morenas1,2, Sergio Helgueta1,2, Laia Muñoz1,2, Jaime Kulisevsky2, Maria Jose Martí2,4, Eduard Tolosa2,3, Jordi Clarimon1,2, Alberto Lleó1,2, Ellen Gelpi3.   

Abstract

Lewy body disorders (LBD) are common neurodegenerative diseases characterized by the presence of aggregated α-synuclein in Lewy bodies and Lewy neurites in the central and peripheral nervous systems. The brains of patients with LBD often display other comorbid pathologies, i.e. insoluble tau, β-amyloid aggregates, TAR DNA-binding protein 43 (TDP-43) deposits, and argyrophilic grain disease (AGD). The incidence and physiological relevance of these concurrent pathological findings remain controversial. We performed a semiquantitative detailed mapping of α-synuclein, tau, β-amyloid (Aβ), TDP-43, and AGD pathologies in 17 areas in 63 LBD cases (44 with Parkinson disease [PD], 28 with dementia, and 19 with dementia with Lewy bodies). APOE and MAPT genetic variants were also investigated. A majority of LBD cases had 2 or 3 concomitant findings, particularly Alzheimer disease-related pathology. Pathological stages of tau, β-amyloid and α-synuclein pathologies were increased in cases with dementia. Aβ score was the best correlate of the time to dementia in PD. In addition, β-amyloid deposition correlated with α-synuclein load in all groups. MAPT H1 haplotype did not influence any assessed pathology in PD. These results highlight the common concurrence of pathologies in patients with LBD that may have an impact on the clinical expression of the diseases.
© 2017 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Copathology; Dementia with Lewy bodies; Parkinson disease; Parkinson disease dementia; Tau; α-Synuclein; β-Amyloid

Mesh:

Substances:

Year:  2017        PMID: 28395086     DOI: 10.1093/jnen/nlx002

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  26 in total

Review 1.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

2.  Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-04-29       Impact factor: 3.575

3.  Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports.

Authors:  Jason W Adams; Victor E Alvarez; Jesse Mez; Bertrand R Huber; Yorghos Tripodis; Weiming Xia; Gaoyuan Meng; Caroline A Kubilus; Kerry Cormier; Patrick T Kiernan; Daniel H Daneshvar; Alicia S Chua; Sarah Svirsky; Raymond Nicks; Bobak Abdolmohammadi; Laney Evers; Todd M Solomon; Jonathan D Cherry; Nurgul Aytan; Ian Mahar; Sherral Devine; Sanford Auerbach; Michael L Alosco; Christopher J Nowinski; Neil W Kowall; Lee E Goldstein; Brigid Dwyer; Douglas I Katz; Robert C Cantu; Robert A Stern; Rhoda Au; Ann C McKee; Thor D Stein
Journal:  J Neuropathol Exp Neurol       Date:  2018-09-01       Impact factor: 3.685

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

5.  Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

Authors:  Yu Iwabuchi; Tohru Shiga; Masashi Kameyama; Raita Miyazawa; Morinobu Seki; Daisuke Ito; Hiroyuki Uchida; Hajime Tabuchi; Masahiro Jinzaki
Journal:  Mol Imaging Biol       Date:  2022-06-14       Impact factor: 3.488

Review 6.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 7.  Morphological basis of Parkinson disease-associated cognitive impairment: an update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-20       Impact factor: 3.850

Review 8.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

9.  A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.

Authors:  Peter J Teravskis; Ana Covelo; Eric C Miller; Balvindar Singh; Héctor A Martell-Martínez; Michael A Benneyworth; Christopher Gallardo; Breeta R Oxnard; Alfonso Araque; Michael K Lee; Dezhi Liao
Journal:  J Neurosci       Date:  2018-09-24       Impact factor: 6.167

Review 10.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.